Electrolyte disturbances represent another important consideration
Kent Bradley, Chief Health and Nutrition Officer at Herbalife, Weight-loss drugs curb your appetite, so people taking medications like GLP-1 Agonist may have difficulty getting all the macronutrients, micronutrients or physical activity they need for optimal muscular, cardiovascular and brain health
Weight loss in particular, but also cardiorenal benefits and other potential advantages, have encouraged wider use, and several further GLP-1RAs with ever longer circulating half-lives are advancing in development, aiming to leverage the convenience of administration with minimal gastrointestinal side effects (Table 2) [37]
Adjust nutrition and exercise as your weight changes
STEP Clinical Trial Program The landmark STEP (Semaglutide Treatment Effect in People with obesity) clinical trial program represents the most extensive investigation of semaglutide for weight management: STEP 1 (New England Journal of Medicine): Enrolled 1,961 adults with obesity or overweight and demonstrated a mean weight loss of 14.9% from baseline at 68 weeks with semaglutide 2.4 mg compared to 2.4% with placebo
However, retatrutide has not yet received regulatory approval from the MHRA, EMA, or FDA, meaning no licensed dosage currently exists
